Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoid tumors

Lisa S. Poritz, Martin Blackstein, Terri Berk, Steve Gallinger, Robin S. McLeod, Zane Cohen

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Abstract

BACKGROUND: Cytotoxic chemotherapy can achieve a good initial response in inoperable desmoid tumors that have caused progressive obstruction of the gastrointestinal and urinary tracts and have caused unrelenting pain. METHODS: We have reviewed 8 patients (3 male) with desmoid tumors and familial adenomatous polyposis who underwent cytotoxic chemotherapy for inoperable gastrointestinal obstruction and/or uncontrolled pain. They were treated with doxorubicin and dacarbazine followed by carboplatin and dacarbazine. RESULTS: Follow-up after cytotoxic chemotherapy in the 7 patients for whom it was available was a mean of 42 (range 24-54) months. Two patients achieved complete remission after therapy. Four patients achieved a partial remission after completing all or some of the chemotherapy regimen; of these, three remained in stable remission, whereas the other was lost to follow-up. There were two recurrences that required further therapy; one of these patients was treated with further chemotherapy, which induced a second remission, and the other was treated with pelvic exenteration and has subsequently died. CONCLUSIONS: Most patients had a substantial response to cytotoxic chemotherapy; however, two patients required additional therapy 24 and 30 months after cytotoxic chemotherapy, respectively. Cytotoxic chemotherapy is effective in producing short-term and long-term remission in these difficult patients.

Original languageEnglish (US)
Pages (from-to)1268-1273
Number of pages6
JournalDiseases of the colon and rectum
Volume44
Issue number9
DOIs
StatePublished - Jan 1 2001

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Fingerprint Dive into the research topics of 'Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoid tumors'. Together they form a unique fingerprint.

Cite this